Procedures for Radiotracers in Cancer PET Studies
Author Information
Author(s): Aboagye E O, Luthra S K, Brady F, Poole K, Anderson H, Jones T, Boobis A, Burtles S S, Price P
Primary Institution: Cancer Research UK
Hypothesis
The document aims to describe procedures for production and safety testing of oncology radiotracers developed for imaging by positron emission tomography in cancer patients.
Conclusion
The proposed procedures ensure patient safety while enabling early pharmacokinetic and pharmacodynamic studies of anticancer agents.
Supporting Evidence
- Radiopharmaceuticals are produced at high specific radioactivity to allow detection of tracer doses in patients.
- The risk to patient volunteers is considered minimal due to the low doses administered.
- The document proposes minimum requirements for product quality and safety testing.
Takeaway
This study talks about how to safely make and test special medicines for cancer patients using a type of scan called PET.
Methodology
The document outlines procedures for the production and safety testing of radiopharmaceuticals, including animal toxicology studies and patient monitoring.
Potential Biases
Potential risks include the lack of extensive safety testing due to the low doses used in tracer studies.
Limitations
The procedures apply only to cancer patients and do not cover studies on healthy volunteers.
Participant Demographics
The studies are conducted on cancer patients, most of whom have incurable disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website